EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

L26/P-797 A single intra-ovarian platelet-rich plasma (PRP) injection is not associated with increased oocyte yield in women with low ovarian reserve: a randomised controlled trial

T. Maier-Eggersmann, J. Martens, N. Hamala, M. Depenbusch, A.R. Hiller, E. Cerniavskaja, M. Meiners, L. Kamalyan, A. Schultze-Mosgau, T. Nagler, G. Griesinger

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.1124 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von T. Maier-Eggersmann und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question What is the efficacy and safety of an autologous intra-ovarian PRP injection prior to IVF/ICSI in women with low ovarian reserve? Summary answer A single intra-ovarian PRP injection prior to IVF/ICSI was not associated with increased oocyte yield versus placebo and showed no safety concerns after 2 years. What is known already Autologous platelet-rich plasma (PRP) contains growth factors and cytokines that support angiogenesis and cellular proliferation. Preliminary human data—initially mainly case reports and small non-randomised studies—suggested follicular activation after intra-ovarian PRP in women with ovarian insufficiency or low reserve. Subsequent studies, including small, randomised trials, have been heterogeneous in design, population, PRP protocols and outcomes, and proposed mechanisms-of-action lack experimental validation. Despite increasing empirical use, robust placebo-controlled randomised trials evaluating intra-ovarian PRP before IVF/ICSI in poor responders are lacking. Study design, size, duration This is a prospective, single-blinded, randomised (4:1), placebo-controlled trial (114 women) with low ovarian reserve. Participants were blinded to allocation and received either a single bilateral intra-ovarian PRP injection (Arthrex ACP®, ArthrexGmbH, ,Germany) or a saline injection before transdermal testosterone (Testogel®) priming and fixed-dose ovarian stimulation (300IU daily recFSH/recLH [Pergoveris®]/GnRH-antagonist protocol, hCG triggering [Ovitrelle® 250µg]). Study duration was lasted 20 weeks (no pregnancy), or 58 weeks (pregnancy occurred). Five-year safety follow up is currently ongoing. Participants/materials, setting, methods Patients aged 18–42yrs with serum AMH<0.5 ng/ml, AFC≤5, eumenorrhoea, both ovaries present, and an indication for IVF/ICSI were included. Participants were blinded and randomised to a single intra-ovarian PRP or saline injection on cycle days 2–5, followed by transdermal testosterone 6.25 mg daily for two cycles before controlled ovarian stimulation. Primary endpoint: number of retrieved cumulus–oocyte complexes; secondary endpoints: hormonal markers, follicular dynamics, pregnancy and neonatal outcomes, patient-reported outcomes, and safety. Main results and the role of chance A total of 114 women were randomised (PRP: n = 91; placebo: n = 23), with a mean age of 37.76 years, serum AMH 0.25 ng/ml, and antral follicle count of 2.81. Sixteen women did not complete the study per protocol, with similar dropout rates in the PRP and placebo groups (14.3% vs. 13.0%). The mean number of retrieved oocytes per randomised patient was comparable between groups (PRP: 2.51 (95 % CI: 2.01-3.01) vs. placebo: 2.40 (95 % CI: 1.46-3.34); p = 0.84), as was oocyte yield (retrieved oocytes per follicle ≥10 mm; PRP: 0.71 vs. placebo: 0.81; p = 0.55). A per-protocol analysis did not materially change the findings. Following the intervention, no significant group-by-time interactions were observed for serum AMH (p = 0.77), FSH (p = 0.43) or antral follicle count (p = 0.68). Follicular number and size distribution on the day of trigger did not differ between groups. Clinical pregnancy rates per per intention-to-treat (ITT) were comparable (PRP: 10.3% vs. placebo: 20.0%; p = 0.33) and a total of seven live births occurred (PRP: 6.4%; placebo: 10.0%). One spontaneous pregnancy occurred following PRP injection. The most frequent adverse event was ovarian cyst formation (PRP: 16.7%; placebo: 5.0%). One severe adverse event occurred in the placebo group (peritonitis requiring hospitalisation). Limitations, reasons for caution The study evaluated a single intra-ovarian PRP injection followed by two cycles of testosterone priming before COS. Alternative PRP protocols or timing may yield different results. The trial was stopped prematurely due to marked recruitment fatigue from late 2024, and the 4:1 randomisation limited precision of secondary outcomes. Wider implications of the findings In this regimen, intra-ovarian PRP did not improve oocyte yield or ovarian reserve markers. These results do not support routine PRP use before IVF/ICSI in women with low ovarian reserve. Further studies should assess alternative protocols. Until then, PRP use in routine care requires careful counselling. Trial registration number Yes

Zitieren

APA

Maier-Eggersmann, T., Martens, J., Hamala, N., Depenbusch, M., Hiller, A., Cerniavskaja, E., Meiners, M., Kamalyan, L., Schultze-Mosgau, A., Nagler, T., & Griesinger, G. (2026). L26/P-797 A single intra-ovarian platelet-rich plasma (PRP) injection is not associated with increased oocyte yield in women with low ovarian reserve: a randomised controlled trial. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1124

Vancouver

Maier-Eggersmann T, Martens J, Hamala N, Depenbusch M, Hiller A, Cerniavskaja E, et al. L26/P-797 A single intra-ovarian platelet-rich plasma (PRP) injection is not associated with increased oocyte yield in women with low ovarian reserve: a randomised controlled trial. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1124

BibTeX
@article{MaierEggersmann2026,
  author = {Maier-Eggersmann, T. and Martens, J. and Hamala, N. and Depenbusch, M. and Hiller, A.R. and Cerniavskaja, E. and Meiners, M. and Kamalyan, L. and Schultze-Mosgau, A. and Nagler, T. and Griesinger, G.},
  title = {L26/P-797 A single intra-ovarian platelet-rich plasma (PRP) injection is not associated with increased oocyte yield in women with low ovarian reserve: a randomised controlled trial},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.1124}
}
Kostenlos starten →